Does Sesame Lipid Profile Randomized Trial work?

Updated October 2026

Quick Answer

Sesame Lipid Profile Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: This comprehensive systematic review and meta-analysis aimed to assess the impact of sesame (Sesamum indicum L.) supplementation on cardiovascular disease risk factors.

Key Takeaways

  • 01This comprehensive systematic review and meta-analysis aimed to assess the impact of sesame (Sesamum indicum L.) supplementation on cardiovascular disease risk factors. [Jafari A (2025)]
  • 02The assessment of study quality was conducted using the Cochrane risk-of-bias tool. [Jafari A (2025)]
  • 03Subgroup analyses revealed that sesame supplementation significantly reduced CRP and malondialdehyde (MDA) in populations without chronic diseases, while total cholesterol (TC) and MDA were reduced in those with chronic diseases. [Jafari A (2025)]
  • 04Relevant research was discovered via PubMed, Scopus, Web of Science, CENTRAL, and EMBASE up to June 2024. [Jafari A (2025)]
The current Migaku evidence database contains 2 reusable source documents for Sesame Lipid Profile Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - This comprehensive systematic review and meta-analysis aimed to assess the impact of sesame (Sesamum indicum L.) supplementation on cardiovascular disease risk factors. [Jafari A (2025); evidence level 1] - The assessment of study quality was conducted using the Cochrane risk-of-bias tool. [Jafari A (2025); evidence level 1] - Subgroup analyses revealed that sesame supplementation significantly reduced CRP and malondialdehyde (MDA) in populations without chronic diseases, while total cholesterol (TC) and MDA were reduced in those with chronic diseases. [Jafari A (2025); evidence level 1] - Relevant research was discovered via PubMed, Scopus, Web of Science, CENTRAL, and EMBASE up to June 2024. [Jafari A (2025); evidence level 1] - Diabetes mellitus and dyslipidemia are significant health concerns that elevate the risk of cardiovascular disease and other metabolic disorders, necessitating effective management strategies. [Fornari Laurindo L (2025); evidence level 1] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Clinical evidence of sesame (Sesamum indicum L.) products and its bioactive compounds on anthropometric measures, blood pressure, glycemic control, inflammatory biomarkers, lipid profile, and oxidative stress parameters in humans: a GRADE-assessed systematic review and dose-response meta-analysis.
  2. Evaluating the effects of seed oils on lipid profile, inflammatory and oxidative markers, and glycemic control of diabetic and dyslipidemic patients: a systematic review of clinical studies.